Search
VPM1002
go.drugbank.com/drugs/DB15801InvestigationalVPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously … [L53263] Although there was no statistically significant difference in overall survival when compared to [crizotinib], ensartinib demonstrated a statistically significant progression-free survival improvement
Ezobresib
go.drugbank.com/drugs/DB15435InvestigationalBMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
Gaboxadol
go.drugbank.com/drugs/DB06554InvestigationalGaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing … Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653]. … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].
Metyrosine
go.drugbank.com/drugs/DB00765ApprovedInvestigationalAn inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra P...
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
XL784
go.drugbank.com/drugs/DB04991InvestigationalResults of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles. … XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors.
Ethylmorphine
go.drugbank.com/drugs/DB01466IllicitInvestigationalIt is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.
Cyclopropane
go.drugbank.com/drugs/DB13984ExperimentalIts use was ultimately limited because it was highly explosive. … Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene.